See more : Atlantic Avenue Acquisition Corp (ASAQ-UN) Income Statement Analysis – Financial Results
Complete financial analysis of Mindset Pharma Inc. (MSSTF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mindset Pharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Top Glove Corporation Bhd. (TGLVY) Income Statement Analysis – Financial Results
- EMVision Medical Devices Ltd (EMV.AX) Income Statement Analysis – Financial Results
- Bravada Gold Corporation (BGAVF) Income Statement Analysis – Financial Results
- Graphex Group Limited (GRFX) Income Statement Analysis – Financial Results
- Club De Futbol Intercity Sad (CITY.MC) Income Statement Analysis – Financial Results
Mindset Pharma Inc. (MSSTF)
About Mindset Pharma Inc.
Mindset Pharma Inc. develops and sells psychedelic medicines to treat neurological and psychiatric disorders in Canada. It focuses on developing MSP-1014, a psychedelic drug candidate. The company is based in Toronto, Canada.
| Metric | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|
| Revenue | 3.91M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 3.91M | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 7.39M | 2.22M | 0.00 | 0.00 |
| General & Administrative | 13.09M | 6.24M | 45.62K | 13.95K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.09M | 6.24M | 45.62K | 13.95K |
| Other Expenses | -33.41K | -71.37K | 0.00 | 0.00 |
| Operating Expenses | 20.48M | 8.46M | 45.62K | 13.95K |
| Cost & Expenses | 20.48M | 8.46M | 45.62K | 13.95K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 44.53K | 22.26K | 171.86K | 161.14K |
| EBITDA | -16.53M | -5.32M | -58.15K | -13.95K |
| EBITDA Ratio | -423.29% | 0.00% | 0.00% | 0.00% |
| Operating Income | -16.58M | -5.35M | -58.15K | -13.95K |
| Operating Income Ratio | -424.43% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -33.41K | -6.31M | 25.04K | 0.00 |
| Income Before Tax | -16.61M | -11.65M | -33.10K | -13.95K |
| Income Before Tax Ratio | -425.29% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 3.12M | 0.00 | 0.00 |
| Net Income | -16.61M | -11.65M | -33.10K | -13.95K |
| Net Income Ratio | -425.29% | 0.00% | 0.00% | 0.00% |
| EPS | -0.18 | -0.20 | 0.00 | 0.00 |
| EPS Diluted | -0.18 | -0.20 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 90.06M | 57.66M | 66.14M | 66.14M |
| Weighted Avg Shares Out (Dil) | 90.06M | 57.66M | 66.14M | 66.14M |
Mindset Pharma says its Family 3 psilocybin analogs demonstrate long-acting duration in preclinical trials
Mindset Pharma Inc announced positive preclinical results from research on its Family 3 group of psilocybin compounds that could significantly improve the sustained effectiveness and safety profile of microdosing practices. The company said in a statement that research on the...
Mindset Pharma files new US patent applications covering its Family 4 novel DMT compounds
Mindset Pharma Inc announced it had filed its new provisional patent application with the United States Patent and Trademark Office that extends its Family 4 compounds, a set of novel DMT/5-MeO-DMT analogs. In a statement, the Toronto-based company said that...
Mindset Pharma Broadens its IP Portfolio by Filing U.S. Provisional Patent Extending its DMT and 5-MeO-DMT Inspired Psychedelic Drug Candidates
TORONTO, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric...
Mindset Pharma advances psychedelic drug candidates' development as its patent applications are published
Mindset Pharma Inc has taken a step further in its bid to establish next-generation psychedelic medicines to treat mental illness, announcing that three of its patent applications for candidates had been published by the Patent Cooperation Treaty (PCT). The three...
Mindset Pharma advances psychedelic drug candidates development as its patent applications are published
Mindset Pharma Inc has taken a step further in its bid to establish next-generation psychedelic medicines to treat mental illness, announcing that three of its patent applications for candidates had been published by the Patent Cooperation Treaty (PCT). The three...
Mindset Pharma reveals new results indicating its psychedelic analogs have greater efficacy and shorter durations compared with reference drugs
Mindset Pharma Inc said that it has successfully demonstrated that its psilocybin analogs have a shorter duration and higher efficacy than typical psychedelics. The Toronto-based company announced results from its preclinical studies on its Family 2 group of novel psilocybin/psilocin...
Mindset Pharma Announces Preclinical Results Demonstrating Superior Efficacy, Safety and Shorter Duration of Action Across Multiple Next Generation Psychedelic Drug Families
Mindset has identified several potential leads across its psilocybin/psilocin and DMT/5-MeO-DMT analogs that demonstrate superior efficacy, safety and shorter duration of action Mindset has identified several potential leads across its psilocybin/psilocin and DMT/5-MeO-DMT analogs that demonstrate superior efficacy, safety and...
Mindset Pharma files international patent application covering its novel psilocybin synthesis process
Mindset Pharma Inc has announced the filing of an international patent application for its novel psilocybin synthesis process. The psychedelic drug company is pioneering a unique process to synthesize psilocybin and psilocin in a faster and more effective manner.
Mindset Pharma is part of an exciting crop of psychedelics firms that are pushing next-generation opportunities
Initially, psychedelics like psilocybin, MDMA, LSD, and DMT were the focus of much of the hard work by non-for-profit groups and academic researchers over the last 30 years, who helped prove that the drugs have potential benefit while being safe and...
Mindset Pharma appoints Dr. Ishrat Husain to its scientific advisory board
Mindset Pharma Inc (CSE:MSET) (OTCQB:MSSTF) (FRA:9DF) has announced the appointment of Dr. Ishrat Husain to the company's scientific advisory board. Mindset said Dr.
Source: https://incomestatements.info
Category: Stock Reports